Leo Pharma Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (27)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Leo Pharma - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Leo Pharma. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “3” cancer drugs in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Leo Pharma - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Leo Pharma - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Leo Pharma. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “3” cancer drugs in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Leo Pharma - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Leo Pharma

  1.1 Business Overview

  1.2 Leo Pharma Pipeline Overview

 

2. Leo Pharma Cancer Drugs in Research Phase

  2.1 Skin Cancer Therapeutics - LEO Pharma/University of Queensland

 

3. Leo Pharma Cancer Drugs in Preclinical Phase

  3.1 Monoclonal Antibody Therapeutics - arGEN-X/Bird Rock Bio

 

4. Leo Pharma Cancer Drugs in Phase-I

  4.1 Teglarinad

 

5. No Development Reported in Cancer Drugs in Clinical Pipeline

  5.1 Ingenol mebutate

 

6. Discontinued in Cancer Drugs in Clinical Pipeline

  6.1 Seocalcitol

  6.2 CHS 828

  6.3 Lexacalcitol

  6.4 PEP 001

  6.5 Tyrosine Kinase Inhibitors - LEO Pharma

  6.6 PEP Compounds - Peplin Limited

  6.7 Matrix Metalloprotease Inhibitors - LEO Pharma

  6.8 CB 1267

  6.9 EB 1213


Figure 1-1: Leo Pharma Cancer Pipeline by Phase (%)

Figure 1-2: Leo Pharma Cancer Pipeline by Phase (Number)

Figure 1-3: Leo Pharma Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Leo Pharma Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)